Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, suggesting that tau phosphorylation may act as an innate immune response in ...

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...

DNL343 is an investigational candidate operated by targeting eukaryotic initiation factor 2B (eIF2B), a key regulator of the integrated stress response. This is considered a new small molecule ...